Elanco Animal Health awarded derivative securities to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen at $24.50 per share on September 4, 2026. The award, classified under transaction code A, represented about 5.4% of his resulting derivative-securities holding, giving investors a precise view of the disclosed executive transaction.
Key Highlights
- The transaction was recorded on September 4, 2026 under transaction code A.
- Robert M. VanHimbergen is Elanco Animal Health’s executive vice president and chief financial officer.
- Elanco awarded derivative securities to CFO Robert M. VanHimbergen at $24.50 per share.
Elanco Animal Health Inc (NYSE: ELAN) awarded derivative securities to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen at $24.50 per share. The transaction represented about 5.4% of his resulting derivative-securities holding. The recipient is identified as an executive officer of Elanco Animal Health.
$24.50 Derivative Award Recorded
VanHimbergen serves as Elanco Animal Health’s executive vice president and chief financial officer. The transaction occurred on September 4, 2026, under transaction code A, a classification used for an award or grant. Elanco’s securities involved were derivatives, and the stated price was $24.50 per share. The reported holding measure is based on the position after the transaction. The transaction details identify the recipient by name and executive title.
Award Classification Separates Transaction Type
Transaction code A identifies an award or grant rather than an open-market purchase, the relevant distinction for investors reviewing the executive transaction. The percentage measures the awarded transaction against that post-transaction derivative position, while the $24.50 figure remains the per-share amount attached to the instruments. That distinction keeps the disclosed activity separate from a market purchase when investors assess executive ownership changes.
FAQs
Q: What did the Elanco Animal Health CFO receive?
A: Robert M. VanHimbergen, Elanco Animal Health’s executive vice president and chief financial officer, received derivative securities in an award or grant transaction. The stated amount was $24.50 per share.
Q: Does the Elanco CFO transaction represent an open-market purchase?
A: No. Transaction code A identifies an award or grant, so the disclosed event is categorized separately from an open-market purchase.
Q: What percentage of the CFO’s holding did the Elanco award represent?
A: The award represented about 5.4% of Robert M. VanHimbergen’s resulting derivative-securities holding. This percentage measures the transaction against his post-transaction derivative position.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.